vs

Side-by-side financial comparison of CREATIVE REALITIES, INC. (CREX) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.

CREATIVE REALITIES, INC. is the larger business by last-quarter revenue ($23.9M vs $18.6M, roughly 1.3× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -8.2%, a 74.0% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 117.2%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 39.5%).

Creative Realities, Inc. is a provider of end-to-end immersive digital experience solutions, including interactive digital signage, content management software, and custom experiential design services. It primarily caters to retail, hospitality, healthcare, corporate workplace, and public sector clients across North America, helping brands enhance customer engagement and operational efficiency.

SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.

CREX vs SCYX — Head-to-Head

Bigger by revenue
CREX
CREX
1.3× larger
CREX
$23.9M
$18.6M
SCYX
Growing faster (revenue YoY)
SCYX
SCYX
+1691.3% gap
SCYX
1808.5%
117.2%
CREX
Higher net margin
SCYX
SCYX
74.0% more per $
SCYX
65.7%
-8.2%
CREX
Faster 2-yr revenue CAGR
SCYX
SCYX
Annualised
SCYX
268.5%
39.5%
CREX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CREX
CREX
SCYX
SCYX
Revenue
$23.9M
$18.6M
Net Profit
$-2.0M
$12.3M
Gross Margin
47.9%
Operating Margin
1.9%
56.3%
Net Margin
-8.2%
65.7%
Revenue YoY
117.2%
1808.5%
Net Profit YoY
30.8%
376.5%
EPS (diluted)
$0.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CREX
CREX
SCYX
SCYX
Q4 25
$23.9M
$18.6M
Q3 25
$10.5M
$334.0K
Q2 25
$13.0M
$1.4M
Q1 25
$9.7M
$257.0K
Q4 24
$11.0M
$977.0K
Q3 24
$14.4M
$660.0K
Q2 24
$13.1M
$736.0K
Q1 24
$12.3M
$1.4M
Net Profit
CREX
CREX
SCYX
SCYX
Q4 25
$-2.0M
$12.3M
Q3 25
$-7.9M
$-8.6M
Q2 25
$-1.8M
$-6.9M
Q1 25
$3.4M
$-5.4M
Q4 24
$-2.8M
Q3 24
$54.0K
$-2.8M
Q2 24
$-615.0K
$-14.5M
Q1 24
$-109.0K
$411.0K
Gross Margin
CREX
CREX
SCYX
SCYX
Q4 25
47.9%
Q3 25
45.3%
Q2 25
38.5%
Q1 25
45.7%
Q4 24
44.2%
Q3 24
45.6%
Q2 24
51.8%
Q1 24
46.9%
Operating Margin
CREX
CREX
SCYX
SCYX
Q4 25
1.9%
56.3%
Q3 25
-68.9%
-2516.5%
Q2 25
-10.2%
-701.0%
Q1 25
-7.4%
-3350.2%
Q4 24
-6.5%
Q3 24
7.9%
-1563.6%
Q2 24
4.5%
-1255.0%
Q1 24
-0.6%
-692.5%
Net Margin
CREX
CREX
SCYX
SCYX
Q4 25
-8.2%
65.7%
Q3 25
-74.5%
-2572.2%
Q2 25
-13.9%
-504.8%
Q1 25
34.6%
-2097.7%
Q4 24
-25.8%
Q3 24
0.4%
-425.5%
Q2 24
-4.7%
-1964.4%
Q1 24
-0.9%
29.9%
EPS (diluted)
CREX
CREX
SCYX
SCYX
Q4 25
$0.25
Q3 25
$-0.75
$-0.17
Q2 25
$-0.17
$-0.14
Q1 25
$0.32
$-0.11
Q4 24
$-0.28
Q3 24
$0.01
$-0.06
Q2 24
$-0.06
$-0.30
Q1 24
$-0.01
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CREX
CREX
SCYX
SCYX
Cash + ST InvestmentsLiquidity on hand
$1.6M
$40.0M
Total DebtLower is stronger
$44.0M
Stockholders' EquityBook value
$21.5M
$49.4M
Total Assets
$151.0M
$59.0M
Debt / EquityLower = less leverage
2.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CREX
CREX
SCYX
SCYX
Q4 25
$1.6M
$40.0M
Q3 25
$314.0K
$37.9M
Q2 25
$569.0K
$44.8M
Q1 25
$1.1M
$40.6M
Q4 24
$1.0M
$59.3M
Q3 24
$868.0K
$68.8M
Q2 24
$4.1M
$73.0M
Q1 24
$2.9M
$80.2M
Total Debt
CREX
CREX
SCYX
SCYX
Q4 25
$44.0M
Q3 25
$22.0M
Q2 25
$19.9M
Q1 25
$23.0M
Q4 24
$13.0M
Q3 24
$10.7M
Q2 24
$13.6M
Q1 24
$12.8M
Stockholders' Equity
CREX
CREX
SCYX
SCYX
Q4 25
$21.5M
$49.4M
Q3 25
$21.9M
$36.4M
Q2 25
$29.4M
$44.5M
Q1 25
$29.9M
$50.5M
Q4 24
$25.5M
$55.1M
Q3 24
$28.3M
$58.5M
Q2 24
$28.2M
$60.4M
Q1 24
$28.8M
$74.1M
Total Assets
CREX
CREX
SCYX
SCYX
Q4 25
$151.0M
$59.0M
Q3 25
$61.3M
$51.1M
Q2 25
$63.7M
$60.7M
Q1 25
$67.0M
$67.9M
Q4 24
$65.2M
$90.6M
Q3 24
$67.6M
$99.0M
Q2 24
$69.6M
$107.8M
Q1 24
$68.2M
$118.3M
Debt / Equity
CREX
CREX
SCYX
SCYX
Q4 25
2.04×
Q3 25
1.00×
Q2 25
0.68×
Q1 25
0.77×
Q4 24
0.51×
Q3 24
0.38×
Q2 24
0.48×
Q1 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CREX
CREX
SCYX
SCYX
Operating Cash FlowLast quarter
$-4.5M
$18.4M
Free Cash FlowOCF − Capex
$-4.6M
FCF MarginFCF / Revenue
-19.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
1.50×
TTM Free Cash FlowTrailing 4 quarters
$-8.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CREX
CREX
SCYX
SCYX
Q4 25
$-4.5M
$18.4M
Q3 25
$-1.6M
$-8.7M
Q2 25
$773.0K
$-7.5M
Q1 25
$-2.4M
$-7.5M
Q4 24
$-1.4M
$-24.0M
Q3 24
$544.0K
$765.0K
Q2 24
$2.3M
$-10.9M
Q1 24
$1.9M
$-4.0M
Free Cash Flow
CREX
CREX
SCYX
SCYX
Q4 25
$-4.6M
Q3 25
$-1.7M
Q2 25
$672.0K
Q1 25
$-2.5M
Q4 24
$-1.4M
Q3 24
$543.0K
Q2 24
$2.3M
Q1 24
$1.9M
FCF Margin
CREX
CREX
SCYX
SCYX
Q4 25
-19.1%
Q3 25
-16.2%
Q2 25
5.2%
Q1 25
-25.2%
Q4 24
-12.5%
Q3 24
3.8%
Q2 24
17.3%
Q1 24
15.7%
Capex Intensity
CREX
CREX
SCYX
SCYX
Q4 25
0.4%
Q3 25
1.0%
Q2 25
0.8%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
CREX
CREX
SCYX
SCYX
Q4 25
1.50×
Q3 25
Q2 25
Q1 25
-0.73×
Q4 24
Q3 24
10.07×
Q2 24
Q1 24
-9.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CREX
CREX

Service And Other$17.3M72%
Managed Services$4.7M20%
Installation Services$1.7M7%

SCYX
SCYX

Glaxosmithkline Intellectual Property$17.2M92%
Products$1.4M8%

Related Comparisons